c v i . s ta n fo rd .e d u | 1

QUARTERLY | FALL 2015AT THE FOREFRONT OF CARDIOVASCULAR MEDICINE

Cardiovascular Institute Annual SymposiumThe Stanford Cardiovascular Institute is hosting its annual symposium in Li Ka Shing Cen-ter on October 27th. For this year’s meeting, leaders from pediatric cardiology, and vas-cular surgery, genetics, health policy, and engineering at Stanford will share their latest research. As cardiovascular disease is the leading cause of death in our country in both men and women, our goal is to provide a venue in which new approaches and solutions are discussed. All medical and research students are welcome and encouraged to attend. The general public is welcome. Attendance is free. List of speakers on page 2.

October 27, 2015 Paul Berg Hall, Li Ka Shing Center, Stanford, CA Register here: http://tinyurl.com/cvi2015

Mark Mercola, PhD was Professor of the Department of Bioengineering, University of California, San Diego and co-founder of the screening cen-ter at the Sanford-Burnham-Prebys Medical Institute. His lab collaborates with engineers to develop tools and instrumentation for high throughput biology, with a focus on high through-put measurements of cardiomyocyte physiology. These technologies enable disease-in-dish assays using pa-tient-specific cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs).

Dr. Mercola discovered the first eukary-otic enhancer sequence, holds a patent on engineered dominant negative proteins, and has authored over 120 ar-ticles. His research at Stanford aims to delineate critical processes in the heart that contribute to a loss of contractile function and can be applied therapeu-tically to restore function.

He co-founded ChemRegen, a biotech company that is commercializing small molecule therapeutics, and is on sever-al advisory boards.

‘Mark is a great addition to our cardio-vascular program at Stanford and we are excited to welcome him to campus.’

- Joseph C. Wu, Director, Stanford

Cardiovascular Institute

THE STANFORD CARDIOVASCULAR INSTITUTE IS PLEASED TO WELCOME DR. MARK MERCOLA

Leah Backhus, MD, MPH, was appointed Associate Professor of Cardiothoracic surgery. Dr. Backhus is a Stanford University gradu-ate who practiced Thoracic Surgery at the University of Washington in Seattle for 5 years before returning to Stanford School of Medi-cine this summer as Associate Professor of Cardiothoracic Surgery. At UW, she developed a reputation as an excellent surgeon, teacher, and Health Services Researcher. Her research, which has been pub-lished in multiple prestigious journals, focuses on imaging in the diagnosis, evaluation, and post-therapy surveillance of non-small cell lung cancer, and also on the impact of segregation and race on lung cancer mortality. She will care for patients at both the Palo

Alto VA and at Stanford Medical Center. She will also serve as Associate Director of the Residency Program for the Thoracic Track component and co-direct a new departmental Center for Health Services Research.

Dr. Backhus joins Dept. Cardiothoracic Surgery

image courtesy of D

r. Fleischmann

c v i . s ta n fo rd .e d u | 2

The Institute currently consists of 124 faculty members representing engineers, physicians,

surgeons, basic and clinical researchers. The mission of the Institute is integrating fundamen-

tal research across disciplines and applying technology to prevent and treat cardiovascular

disease. To support cardiovascular research and education at CVI, please contact Cathy Hut-

ton, Senior Associate Director, Medical Center Development (cathy.hutton@stanford.edu) or

Dr. Joseph C. Wu, Director CVI ( joewu@stanford.edu), or Ingrid Ibarra, Assistant Director of

CVI, (iibarra@stanford.edu).

For more information: http://cvi.stanford.edu/waystogive.html and http://cvi.stanford.edu

About the Stanford Cardiovascular Institute

Cathy Hutton Ingrid Ibarra, PhD

SPEAKERS | Cardiovascular Research Symposium

Garret A. FitzGerald, MD McNeil Professor Translational Medicine and Therapeutics University of Pennsylvania

Clyde W. Yancy, MD Chief, Division of Medicine Northwestern University Feinberg School of Medicine

Dean Lloyd B. Minor, MD The Carl and Elizabeth Naumann Professorship for the Dean of the School of Medicine, Professor of Otolaryngology—Head & Neck Surgery and, by courtesy, of Neurobiology and Bioengineering

Marlene Rabinovitch, MD Dwight and Vera Dunlevie Professor in Pediatric Cardiology

Brian Kobilka, MD Helene Irwin Fagan Chair in Cardiology, Professor, by courtesy, of Chemical and Systems Biology, 2012 Nobel Laureate in Chemistry

Thomas Quertermous, MD William G. Irwin Professor in Cardiovascular Medicine, Chief, Division of Cardiology

Matthew Mell, MD Associate Professor Surgery (Vascular Surgery)

Paul Heidenreich, MD Professor of Medicine (Cardiovascular) and, by courtesy, of Health Research and Policy at the Palo Alto Veterans Affairs Health Care System

Matthew Porteus, MD, PhD Associate Professor of Pediatrics

Todd Brinton, MD Clinical Associate Professor Cardiovascular Medicine

Register at: http://med.stanford.edu/cvi/support-our-research/2015-cv-research-at-stanford.html

Alison Marsden, PhD Associate Professor of Pediatrics (Cardiology) and of Bioengineering and, by Courtesy, of Mechanical Engineering

KEYNOTE SPEAKER KEYNOTE SPEAKER

c v i . s ta n fo rd .e d u | 3

I wrote a press release recently on a study that showed a high percentage of donat-ed hearts were not being used, raising concerns that some were getting wasted when they could be used to save lives. This made me curious about the process of just how a donor heart, which ideally has about a two-hour window before it gets transplanted to a patient with heart failure, gets matched.

The result is a Stanford Medicine maga-zine story titled “Heart Choices” that de-scribes this process, the tough decisions that family members make when a loved one donates a heart, and the excruciating waiting that patients in need of a new heart go through.

Most importantly the article asks the ques-tion: Should more “high-risk” donor hearts be used? An estimated 20,000 people across the country are waiting for new hearts, and only a few thousand transplants happen on

average per year. My story explains the di-lemma:

The general assumption is that there simply

are not enough donor hearts available to

meet a growing demand. But new research

is questioning that assumption. Some re-

searchers and surgeons claim that thou-

sands of donor hearts that could be used

are turned away each year. The hearts are

considered marginal because they come

from older, sicker or riskier donors, but many

argue they are safe for transplant, and could

be saving lives.

“As patients wait longer, they often get sick-

er, and we often lose patients,” says Stan-

ford cardiologist Kiran Khush, MD, whose

research reports that 65 percent of available

heart donations are discarded because of

stringent acceptance criteria. Yet the criteria

have not been critically evaluated, she says.

“Increasing the supply of donor hearts is, of

course, a great concern of mine.”

SPEAKERS | Cardiovascular Research Symposium

Are Donor Hearts Getting Wasted?By Tracie White

Robotically Assisted Coronary Artery Bypass GraftingTo develop innovative treatments for Coronary Artery Disease (CAD), Stanford has designed a program that brings together, preventative cardiologists, interventional cardiologists, and cardiothoracic surgeons: the Advanced Coro-nary Revascularization Program (ACR).

Jack H. Boyd, MD, Clinical Assistant Professor, Cardiothoracic Surgery, leads the surgical arm of the program and focuses on minimally invasive approaches to surgical revascularization. For example, Hybrid Coronary Revascular-ization (HCR), combines the advantages of two standard treatments, Coronary Artery Bypass Grafting (CABG) and Percutaneous Coronary Interventions (PCI). The combinatorial approach has survival benefits and avoids median sternotomy and prolonged recovery.

Boyd, along with a dedicated multidisciplinary cardiac care team, performed the first robotically-assisted coronary revascularization in Northern California, using the da Vinci Xi Surgical System. Utilizing robotic technology offers patients yet another alternative to traditional open-heart surgery and yields faster recoveries with decreased discomfort and trauma.

The Stanford ACR team will continue to push boundaries for revascularization treatments.

http://scopeblog.stanford.edu/2015/07/23/are-donor-hearts-getting-wasted/

Jack H. Boyd, MD

Kiran Khush, MD

Illustration by Paul Blow

c v i . s ta n fo rd .e d u | 4

Atrial fibrillation (AF) is the most com-mon form of cardiac arrhythmia af-fecting over two million people in the United States alone. Today, the standard for treating AF is using (radiofrequency, cryo-ablation) catheters. Cardiac abla-tion methods have a high rate of failure: the procedure fails to cure at least 27% of the population after the first procedure with a 6% chance of serious complica-tions arising during the operation. We propose a robotic system that autono-mously traces the atrial chambers to de-liver pre-planned ablation treatments.

‘Autonomous Ablation Treatment of Cardiac

Arrhythmia Using Robotic Catheters’

Currently, it takes an average of about 10 years to bring a new chemical entity to the mar-ket at an estimated cost of about $1.4 billion. Herein we propose to screen the Food & Drug Administration (FDA) approved known drug molecules using stem cells, to develop better understanding of their mode-of-action. Results of our systematic study will allow for repurposing of such molecules towards disease(s) with better/effective therapeutic outcomes. Importantly also, it will enable in designing new molecular entities for drug discovery/development.

‘Defining the Role of Immune Biomarkers in Non-ST Elevation Myocardial Infarction: Analysis from TRACER Trial Biorepository’

Despite improvement in clinical manage-ment, non-ST elevation acute coronary syn-drome (NSTE-ACS) remains a major cause of mortality and morbidity. There is an unmet need to identify key immune mediators of major cardiovascular events including car-diovascular death, heart failure, recurrent MI or stroke. The role of inflammation in the pathophysiology in NSTE-ACS has been well established using both experimental and clinical biomarkers studies. We aim to identify a cytokine and growth factor profile associated with recurrent MI in patients admitted for NSTEMI as part of the TRACER trial.

The Stanford Cardiovascular Institute has provided over $2.5 million in seed funding to support research in all areas of cardiovascular research and technology development since 2004. Our goal is to ignite and support new ideas that will change how we diagnosis and treat cardiovascular dis-eases. Together with Stanford Children’s Health, CVI will support eight projects out of 43 submissions for 2016.

Awarding New Ideas2016 Seed Grant Recipients

David Camarillo, PhD Paul Wang, MD

Sanjay V. Malhotra, PhD, FRSC

Sayed Nazish, PhD

Chun Liu, PhD

‘Stem Cell Based Mechanistic Study of FDA Approved Drugs for Repurposing of their Drug Actions’

Kenneth Mahaffey, MD

Francois Haddad, MD

Holden Maecker, PhD

Robert Harrington, MD

Ryan O’Malley, MD

c v i . s ta n fo rd .e d u | 5

‘A Pilot Study for an Engineered HGF Fragment for the Treatment of Myocardial Infarction in a Preclincal Ovine Model’An estimated 20 million Americans suffer from coronary artery disease and 6 million have heart fail-ure. Over 1 million a year have acute myocardial infarction (MI) with a short-term mortality that still exceeds 7% despite maximal aggressive therapy. We will evaluate the efficacy of a novel engineered

peptide, HGF-f in a large animal model of ischemic cardiomyopathy. We hypothesize that there are physiologic and anatomic differences between small animals and humans related to size and myocardial thickness that will be best refined in the preclinical large animal model.

‘MicroRNA Regulation of Blood Brain Barrier Function and Hypoperfusion- induced Cerebrovascular Disease’

Several neuronal dis-eases such as isch-emic and hemorrhagic stroke and vascular de-mentia are associated with cerebral vascular injuries or patholo-gies. An understanding

of the molecular mechanisms regulating blood brain barrier permeability and dis-ruption is required for establishing effica-cious therapeutic strategies.

‘Regulation of Abdominal Aortic Aneurysm Pathogen-esis by Hypoxia Inducible factors (HIF)’

Abdominal aortic aneu-rysm is a degenerative inflammatory disease affecting one million adult Americans. While much has been learned regarding aneurysm pathogenesis, no such discovery has been

successfully translated to clinical patient care. While expansive and highly morbid, to date surgical repair is the only effective treatment. Novel targets for developing pharmacological therapy for aneurysm disease is needed.

Philip Tsao, PhD

‘T-Cell Deficiencies in Adult Congenital Heart Disease’

Patients with congenital heart disease (CHD) are now surviving into adulthood, when the patients of-ten face challenges including those associated with aging, worsening heart function, and the need for cardiac transplantation. We have now identified 110 patients with Fontan physiology of 1000+ adult CHD patients managed over the past ~20 years at Stan-ford. We will test in adult CHD patients the hypoth-esis that early thymectomy diminishes the ability to make new T cells, causing an immune deficiency with important clinical consequences in adult life, including susceptibility to infection, increased senescence of lymphocyte popu-lations, and increased inflammation.

Ronald L. Dalman, MD

Anitra Romfh, MD

Manish Butte, MD, PhD

‘Modeling Chronic Chagasic Cardiomyopathy Disease Mechanisms Using Human Induced Pluripotent Stem Cells’

Chagas’ disease, caused by the hemoflagellate pro-tozoan Trypanosoma cruzi (T. cruzi), is one of the world’s most neglected tropical diseases affecting about 8 millions people in Latin America. We pro-pose to use human pluripotent stem cell derived car-diomyocytes (PSC-CMs) to model the disease. This will allow us to gain insight into the mechanisms of T.

cruzi invading human cardiomyocytes and suppress-ing their cellular immune response.

Y. Joseph Woo, MDAmanda Steele

Evgenios Neofytou, MD

David Stevens, MD

c v i . s ta n fo rd .e d u | 6

Scientists at the Stanford University School of Medicine and their colleagues have enabled damaged heart tissue in an-imals to regenerate by delivering a protein to it via a bioengineered collagen patch.

“This finding opens the door to a completely revolutionary treat-ment,” said Pilar Ruiz-Lozano, PhD, Associate Professor of Pediatrics at Stanford. “There is currently no effective treatment to reverse the scarring in the heart after heart attacks.”

The work is described in a paper published online Sept. 16 in Nature. Ruiz-Lozano is the senior author. Vahid Serpooshan, PhD, a postdoc-toral scholar in cardiology at Stanford, and Ke Wei, PhD, a postdoctoral scholar at the University of California-San Diego, share lead authorship.

In a heart attack, cardiac muscle cells, called cardiomyocytes, die from a lack of blood flow. Replacing those dead cells is vital for the organ to fully recover. Unfortunately, the adult mammalian heart does not regenerate effectively, causing scar tissue to form.

The article, titled “Epicardial FSTL1 reconstitution regenerates the adult mammalian heart”, was published in Nature. 2015 Sept. The authors include: Ke Wei, Vahid Serpooshan, Cecilia Hurtado, Mar-ta Diez-Cuñado, Mingming Zhao, Sonomi Maruyama, Wenhong Zhu, Giovanni Fajardo, Michela Noseda, Kazuto Nakamura, Xueying Tian, Qiaozhen Liu, Andrew Wang, Yuka Matsuura, Paul Bushway, Wenqing Cai, Alex Savchenko, Morteza Mahmoudi, Michael D. Schneider, Maurice J. B. van den Hoff, Manish J. Butte, Phillip C. Yang, Kenneth Walsh, Bin Zhou, Daniel Bernstein, Mark Mercola & Pilar Ruiz-Lozano.

Pilar Ruiz-Lozano, PhD

A Cheaper, Faster Way to Find Genetic Defects in Heart Patients By Jennie Dusheck

In most people, heart disease develops through a lifetime of cigarettes, trans fats or high glycemic foods. For only a minority of patients does the cause lie in their genes. But when such atypical patients show up for treatment, figuring out why their hearts aren’t working has been a huge challenge for their doctors.

The process of deciding if a heart patient’s problem is genetic and, if so, which gene defects might be causing the problem can take weeks or months, cost a thousand dollars or more, and, at the end, leave physicians still scratching their heads over a mountain of uncertain data.

A new genetic test being developed by pathologist Kitchener Wilson, MD, PhD, car-diology and radiology professor Joseph Wu, MD, PhD, and the Stanford Genome Technology Center (SGTC), may be able to accurately pinpoint the likely genetic causes of a heart patient’s elusive condition in just a couple of days.

Wilson and Wu say that for a patient with a heart condition that’s difficult to diagnose, it makes no sense to sequence the entire 22,000-gene human genome. Such whole-genome sequencing is costly, time consuming, and produces data marred by small but important errors.

So, taking a more focused approach, Wilson and Wu’s team designed a streamlined assay, or test, that looks at just the 88 genes known to carry mutations that cause heart problems. Materials for the new assay cost about $100, and results are back within three days.

Their approach—surveying a small subgroup of relevant genes instead of the whole genome—is already used to look for other genetic diseases, such as cystic fibrosis. But cystic fibrosis results from mutations in a single gene. “The heart diseases are more challenging just because there are so many genes to sequence,” says Wilson.

Wilson and Wu’s assay is a variation on “complementary long padlock probes,” or cLPPs, a class of genetic probes developed by Curt Scharfe, MD, PhD and Peidong Shen, PhD at the SGTC. These simple probes accurately target specific parts of the genome and are easily customized to target genes of interest. Wilson, Wu, Scharfe, and Shen spearheaded the effort to put cLPPs to work on genes connected with heart problems and reported their work in the journal Circulation Research, with Wu as senior author and Wilson as first author.

This work was published in Circulation Research, 2015 Sept. Authors include: Kitchener D. Wilson*, Peidong Shen*, Eula Fung, Ioannis Karakikes,

Angela Zhang, Kolsoum InanlooRahatloo, Justin Odegaard, Karim Sallam, Ronald W. Davis, George K. Lui, Euan A. Ashley, Curt Scharfe, Joseph C. Wu

See more at http://scopeblog.stanford.edu/2015/08/11/cheaper-faster-way-to-find-genetic-defects-in-heart-patients/

Delivering Missing Protein Heals Damaged Hearts in Animals, Stanford-led Study Finds By Tracie White Medical School’s Office of Communication & Public Affairs

Volume 117, Number 7, September 11, 2015ISSN 0009-7330http://circres.ahajournals.org

AmericanHeartAssociation®

CirculationResearch

cLPP NGS Assay for Inherited Heart Diseases p 603Kv1.5 Channels in Coronary Metabolic Dilation p 612Adrenergic Repression of MeCP2 p 622eNOS Gene-Enhanced Cell Therapy for PAH p 645

Kitchener Wilson, MD, PhD

Curt Scharfe, MD, PhD

c v i . s ta n fo rd .e d u | 7

Members of the Stanford Cardiovascular Institute were invited to the Vår Gård in Saltsjöbaden, Sweden to participate in the Annual Karolinska Institute Cardiovascular Program Retreat. The cardiovascular program at KI has the vision to work “from bedside to bench and back” in order to address relevant clin-ical problems and fast translate new mechanistic insights into innovative prevention, diagnostics and therapy. Presenting their latest research were Stanford faculty: Thomas Quertermous, MD, Professor in

Cardiovascular Medicine; Philip Tsao, PhD, Professor of Medicine (Cardiovascular Medicine); Nicholas Leeper, MD, Assistant Professor of Surgery (Vascular Surgery); and Joseph C. Wu, MD, PhD, Director of the Stanford Cardiovascular Institute.

Tension Helps Heart Cells Develop Normally, Stanford Study Shows By Amy Adams

Tension might not be fun for us, but it looks like it’s critical for our hearts. So much so that without a little tension heart cells in the lab fail to develop normally.

This is a finding that took a mechanical engineer looking at a biological prob-lem to solve. For many years now scientists have been able to mature stem cells into beating clumps of cells in the lab. But although those cells could beat, they didn’t do it very well. They don’t produce much force, can’t main-tain a steady rhythm and would be a failure at pumping actual blood.

Beth Pruitt, PhD, a Stanford Mechanical Engineer, realized that in our bodies heart cells are under considerable tension, and thought that might be critical to how the cells develop.

She and postdoctoral scholar Alexandre Ribeiro started investigating how heart cells matured in dif-ferent shapes and under different amounts of tension. They found a combination that produces nor-mal looking cells with strong contractions.

The work could be useful for scientists hoping to replace animal heart cells as the gold standard for identifying heart-related side effects of drugs. Those cells are quite different from our own and often fail to detect side effects that could damage hearts in people taking the drug.

“We hope this can be a drop-in replacement for animal cells, and potentially instead of having to do individual recordings from each cell we could use video analysis,” said Riberio

Article, “Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness,” was published in Proc Natl Acad Sci U S A. 2015 Sept. Authors include: Alexandre J. S. Ribeiro, Yen-Sin Ang, Ji-Dong Fu , Renee N. Rivas, Tamer M. A. Mohamed, Gadryn C. Higgs, Deepak Srivastava, Beth Pruitt.

See more at: http://scopeblog.stanford.edu/2015/09/30/tension-helps-heart-cells-develop-normally-stanford-study-shows/

Annual Karolinska Institute Cardiovascular Program Retreat

Beth Pruitt, PhD Alexandre Ribeiro, PhD

Philip Tsao with Lars Maegdefesse (left), Thomas Quertermous (middle) and Nicholas Leeper (right), showcasing Stanford research at the 2015 Annual KI retreat.

c v i . s ta n fo rd .e d u | 8

Lucile Packard Children’s Hospital Stanford Plans Major Expansion of its World-renowned Heart CenterBy Robert Dicks

The largest, most experienced pediatric heart surgery program on the West Coast performs over 600 surgeries a year, and plans for more ca-pacity through expansion

It’s a very exciting time for Lucile Packard Children’s Hospital Stanford and Stanford Children’s Health.

This month marks a two-year countdown to the opening of the hos-pital’s $1.1 billion, 521,000 square foot expansion. Almost doubling

the size of the current hospital and adding 149 patient beds, the expansion and new main building will increase access to America’s most advanced and family-friendly hospital for children and expectant mothers.

The September 2017 opening will ensure that families who need high-quality care aren’t turned away due to lack of space. It will also provide a launching pad for expanding and renovating the current hospital next door. This will include creating room to grow the na-tionally-ranked Pediatric Heart Center, which due to demand will premiere a new and larg-er space in 2018.

“This is excellent news for patients and their families,” said Stephen Roth, MD, MPH, Di-rector of the Heart Center with famed pediatric cardiothoracic surgeon and Heart Center executive director, Frank Hanley, MD. “Expanding our Heart Center means that even more children with complex heart problems, as well as growing numbers of adult survivors of congenital heart disease, will have access to one of America’s most advanced programs. Many of these children and adult survivors have run out of options elsewhere.”

Full story: http://www.stanfordchildrens.org/en/about/news/releases/2015/stanford-childrens-plans-expansion-of-world-renowned-heart-center

DNA Damage Seen in Patients Undergoing CT Scanning By Tracy White

Using new laboratory technology, scientists have shown that cellular damage is detectable in patients after CT scanning, according to a new study led by researchers at the Stanford Univer-sity School of Medicine.

“We now know that even exposure to small amounts of radiation from computed tomagraphy scanning is associated with cellular damage,” said Patricia Nguyen, MD, one of the lead authors of the study and an Assistant Professor of Medicine (Cardiovascular Medicine). “Whether or not this causes cancer or any negative effect to the patient is still not clear, but these results should encourage physicians toward adhering to dose-reduction strategies.”

The article, titled “Assessment of the Radiation Effects of Cardiac CT Angiography Using Protein and Genetic Biomarkers” was pub-lished in JACC Cardiovasc Imaging. 2015 Aug. Authors include: Patricia K. Nguyen, Won Hee Lee, Yong Fuga Li, Wan Xing Hong, Shijun Hu, Charles Chan, Grace Liang, Ivy Nguyen, Sang-Ging Ong, Jared Churko, Jia Wang, Russ B. Altman, Dominik Fleischmann, Joseph C. Wu. This article received press coverage by CBS news, Fox News and other major news outlets.

By the Numbers: Last Year at the Pediatric Heart Center

• 6,600 outpatient visits

• More than 600 heart surgeries, and another 500 surgeries at Heart Center partner programs: UCSF Benioff Children’s Hospital Oakland, Sutter Memorial Center in Sacramento, and Valley Children’s Hospital in Madera

• 25 heart transplants

• 16 ventricular assist device implants

• 8,238 transthoracic echocardiograms

• 1,030 admissions to the Cardiovascular Intensive Care Unit

• 20 clinical trials currently under way

Stephen Roth, MD

Dominik Fleischmann, MD

Patricia Nguyen, MD

c v i . s ta n fo rd .e d u | 9

As part of the mission to create a new more effective approach to clinical research, the Stanford Center for Clinical Research (SCCR) held their first training program in September. The class covered basic principals of cardiac anatomy & physiology, con-duction and interpreting EKG.

Susan Fernandes, LPD, PA-C, Director of the Adult Congenital Heart program and Clinical Associate Professor of Pediatrics led the lectures along with Rhonda Larsen, PA-C, MHS, Clin-

ical Assistant Professor, Pediatrics – Cardiology. SCCR, aims to seamlessly integrate aca-demic expertise and business objectives to meet the needs of clinical research sponsors. Their affiliation with Stanford faculty members allows invaluable scientific leadership.

For more on SCCR visit: http://med.stanford.edu/sccr.html

Cardiometabolic Diseases The Palo Alto Veterans Affairs (VA) hospital funded four new studies that will use genetic and other data from its Million Veteran Program (MVP) to answer key questions on heart dis-ease, kidney disease, and substance use—high-priority condi-tions affecting Veterans. MVP is currently the nation’s largest biobank having enrolled over 390,000 veterans.

Cardiovascular Institute researchers Phil Tsao, PhD, and Tim Assimes, MD, PhD, as well as Stanford faculty, Hua Tang, PhD,

and Jennifer Lee, MD, PhD, were awarded one of the first grants to study the genetics of cardiometabolic diseases. The consortium in-cludes investigators from five VA hospitals (Palo Alto, Philadelphia, Phoenix, Bedford, and Albany) as well as the University of Pennsylva-nia. The goal is to establish an analytic pipeline to link clinical data from the VA electronic health records to genome wide genetic data generated in the first 200,000 MVP participants.

The National Institutes of Health’s Undiagnosed Diseases Network launched in September, and Euan Ashley, MRCP, DPhil, Associate Professor of cardiovascular medicine and of genetics at the Stanford University School of Medicine, has been named co-chair of the UDN steering committee.

The network, which seeks to provide answers for patients with mysterious conditions and to advance medical knowl-edge of both rare and common diseases, is an outgrowth of a smaller NIH program begun in 2008 called the Undiag-nosed Disease Program. The new, expanded network inaugurates an online application gateway for patients, called the UDN Gateway, that will harness the expertise of physicians at six major medical centers across the United States, while integrating patient access, patient consent forms and patient genome and other data through a single Internet portal. Within two years, the UDN expects to handle 250 patients per year.

For more visit: https://med.stanford.edu/news/all-news/2015/09/5-questions-euan-ashley-on-diagnosing-the-undiagnosable.html

A National Program to Diagnose Difficult-to-Diagnose Patients is Taking RootBy Jennie Dusheck Medical School’s Office of Communication & Public Affairs

Building a Solid Foundation

Philip Tsao, PhD Tim Assimes, MD, PhD

Hua Tang, PhD Jennifer Lee, MD, PhD

Euan Ashley, MRCP, DPhil

c v i . s ta n fo rd .e d u | 10

Jennifer Tremmel, MD, Assistant Professor of Medicine, was appointed the Susan P. and Riley P. Bechtel Medical Director, an endowed position that supports her existing role as the Clinical Di-rector of the Women’s Heart Health Program at Stanford Health Care. The focus of Dr. Tremmel’s

research is sex differences in cardiovascular disease. She stud-ies how men and women differ in coronary endothelial func-tion, plaque deposition and the circulation of blood in the smallest blood vessels in men and women who have chest pain despite having normal-appearing coronary arteries. Dr. Tremmel is the inaugural holder of the Directorship.

Ronald Witteles, MD, was promoted to As-sociate Professor of Medicine. Dr. Witteles is program Director of the Internal Medicine Residency Training Program at Stanford, and oversees all fellowship programs within inter-

nal medicine. He is also Co-Director of the Stanford Amyloid Center, the largest center of its kind in the western United States. His research focuses on emerging treatments for sys-temic amyloidosis, cardiac complications of cancer therapy, and evolving diagnostic/therapeutic strategies for cardiac sarcoidosis.

Alison Marsden, PhD, was appointed Associate Professor of Pediatrics and of Bioengineering. Marsden specializes in pediatric and congenital heart disease, using simulations of blood flow to improve medical device design and imaging, and to study the progression of heart disease.

She also works with clinical researchers to develop tools for personalized medicine and treatment planning.

In the summer, the Cardiovascular Institute initiated a new postdoctoral fellow research award. The award was established to support scholars with promising research. Next deadline will be in the Winter 2016 visit cvi.stanford.edu for details.

Postdoctoral Research Award

Notable People

Guang Li, PhD Sean Wu lab

Characterization of atrial cardiomyocyte lineage com-mitment at single cell level

Mingtao Zhao, PhD Joseph C. Wu lab

Epigenetic mechanisms of phenotypic maturation of human iPSC-derived

endothelial cells

Arjun Adhikari, PhD James Spudich lab

The effect of pediatric specific HCM mutations on β cardiac myosin power

generation

Jin Qian, PhD Mark Nicolls lab

The role of leukotriene B4 in the develop-ment of pulmonary arterial

hypertension

c v i . s ta n fo rd .e d u | 11

Sanjiv Narayan, MDNIH |‘The Maintenance of Human

Atrial Fibrillation’

Russ B. Altman, MD, PhD NIH | ‘Text Mining for

High-fidelity Curation and Discovery of Gene-drug-

phenotype Relations’

Craig Levin, PhDNIH | ‘RF-penetrable PET Ring

for Acquiring Simultaneous Time-of-flight PET and MRI

Data’

Dwight G. Nishimura, PhDNIH | Coronary Magnetic Resonance Angiography

Alex Dunn, PhD NIH | Understanding Force-

dependent Binding of Alpha-catenin to Actin

Mary Frances Teruel, PhDNIH | ‘Controlling Tissue Size by

Noise and Feedback’

Seda Tierney, MDAHA | On-line Intervention to Lower

Cardiovascular Risk in Pediatric Heart Transplant Patients

Daria Mochly-Rosen, PhDNIH | ‘Molecular

Pharmacology Training Grant’

Recently Awarded Projects

Fan Yang, PhD

CIRM | ‘Injectable Macroporous Matrices to Enhance Stem Cell

Engraftment and Survival’

Jeffrey A. Feinstein, MD Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Richard-Tien Van Ha, MDHeartMate® III IDE Clinical Study Protocol

Ronald M. Witteles, MDA Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Roham T. Zamanian, MDA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension

New Clinical Trials

Faculty Search

The Department of Medicine and the Cardiovascular Institute at the Stanford University School of Medicine seek a clinical investigator to join the Department as Assistant Profes-sor or Associate Professor or Professor in the University Tenure Line (UTL) or the Medical Center line (MCL). For more information visit: http://med.stanford.edu/cvi.html

c v i . s ta n fo rd .e d u | 12

Through a generous gift, the Stanford Cardiovascular Institute established its first fund for Stanford Medical students. Students select 124 faculty at Stanford across diverse disciplines. We called it iHeart Research because it takes a passion for solving problems and dedication to the one disease that continues to be the number one cause of death. Applications will be accepted until end of 2015.

Links to:

» Our Members » Research Disciplines

Questions? Contact iibarra@stanford.edu http://med.stanford.edu/cvi/research/i-heart-research-award.html

Funding Opportunities

POSTDOCTORAL FELLOWSOCTOBER K01 Mentored Research Scientist Development Awards Deadline: Oct. 12, 2015 PA-14-044

K08 Mentored Clinical Research Career Development Award Deadline: Oct. 12, 2015 PA-14-046

K23 Mentored Patient-Oriented Research Career Development Award Deadline: Oct. 12, 2015 PA-14-049

K99/R00 NIH Pathway to Independence Award Deadline: Oct. 12, 2015 PA-15-083

NOVEMBER A.P. Giannini Foundation Postdoctoral Research Fellowship Amount of funding: $46-50K for 3 years Deadline: Nov. 3, 2015 Giannini Postdoc

Stanford University Cardiovascular Institute CVI Travel & Exchange Ideas Award Deadline: Nov. 15, 2015

Prevention Research Center Fellowship Deadline: Nov. 15, 2015 Prevention Research Fellowship

DECEMBER

National Institutes of Health POSTDOCS PA-14-149 Kirschstein National Research Service Award (F32) Deadline: Dec. 8, 2015 PA-14-149

MONTHLY CVIFACULTY CLUB

Discuss your latest research or just unwind

with your peers with wine & cheese

Monthly, 4:30 p.m.

in Lorry Lokey G1161

Grant Details: The application includes a:

• Two-page proposal • One letter of recommendation

Award Perks:

• Up to a $15,000 stipend • Choose a mentor from a list of faculty

at Stanford specializing in surgery, en-gineering, health policy stem cells and regenerative medicine etc.

This new meet-up is composed of cardiovascular and pulmonary postdoctoral fellows and students. All are welcome to join in on research discussion and collaborations over beer and light appetizers.

Organizers: Elda Dzilic, MD, Jared Churko, PhD, Jan Hennings, MD, Kiril Penov, MD

Next event: 5 p.m., Dec. 3! Lorry Lokey (SIM1) building.

CVI Scholars and Graduate Student Meet-up.

Be part of the

conversation!

c v i . s ta n fo rd .e d u | 13

OCTOBER

Transcatheter Cardiovascular Therapeutics (TCT) 2015 October 11 - 15, 2015 San Francisco, CAhttp://www.crf.org/tct

Vascular Biology (NAVBO – North American Vascular Biology) October 18–22, 2015 Hyannis, MAhttp://www.navbo.org/events/vascular-biology-2015

Cardiac Safety Research Consortium (CSRC) Roudtable Discussion: Cardiovascular Safety for Cell Therapies in Development for Cardiovascular Indications October 23, 2015 Beltsville, MDhttp://cardiac-safety.org/

NOVEMBER

American Heart Association Scientific Sessions 2015 November 7 – 11, 2015 Orlando, Florida AHA 2015

VEITH-Vascular Endovascular Issues Techniques Horizons November 17-21, 2015 New York, NYhttp://www.veithsymposium.org/index.php?pg=register

Patricia Nguyen, MD

Mintu Turakhia, MD

Upcoming Cardiovascular Conferences

Dr. Adams is a leader in the field of heart valve surgery and mitral valve reconstruction. As the Marie-Josée and Henry R. Kravis Professor of Cardiovascular Surgery and Program Direc-tor of The Mount Sinai Hospital’s Mitral Valve Repair Reference Center, he has set national benchmarks with > 99% degenera-tive mitral valve repair rates, while running one of the largest programs in the United States.

Lunch provided.

Registration encouraged.

Register here: http://tinyurl.com/cohn2015

The InauguralLawrence H. & Roberta Cohn Lecture

12 - 1 p.m., Mon. Nov. 2Li Ka Shing Center, Paul Berg Hall B & C

291 Campus Drive, Stanford, CA

David Adams, MD, Professor and System Chair Cardiovascular Surgery

Mount Sinai Hospital

c v i . s ta n fo rd .e d u | 14

Frontiers in Cardiovascular ScienceLunch with Leaders in Cardiovascular Research and Medicine: Tuesdays | 12 - 1 p.m. | LKSC

OCTOBER 20, 2015 Michael R. Bristow, MD, PhD Professor of Medicine, Cardiology CU Cardiovascular Institute (CU CVI)

NOVEMBER 17, 2015 Hesham Sadek, MD, PhD Assistant Professor UT Southwestern Medical Center

DECEMBER 01, 2015 Donald M. Bers, PhD Professor and Chair, Department of Pharmacology University of California, Davis

DECEMBER 08, 2015 Anthony Rosenzweig, MD Professor and Chief, Cardiovascular MedicineHarvard, Massachusetts General Hospital

DECEMBER 15, 2015 Gordon F. Tomaselli, MD, Professor and Chief, Cardiovascular Med-icine, Johns Hopkins University

JANUARY 12, 2016 Stanley Hazen, MD, PhDDepartment Chair, Dept. of Cellular and Molecular Medicine, Cleveland Clinic

JANUARY 19, 2016 Jonathan Seidman, PhDProfessor, Department of Genetics, Har-vard Medical School

FEBRUARY 16, 2016 Eric J. Topol, MDDirector, Scripps Translational Science Institute

MARCH 1, 2016 Todd Rosengart, MD, FACSProfessor of Surgery and DeBakey-Bard Chair of Surgery, Baylor

MARCH 8, 2016 Jonathan S. Stamler, MDDirector, Harrington Discovery InstituteCase Western Reserve University

MARCH 15, 2016 Linda L. Demer, MD, PhDVice Chair of Cardiovascular and Vascular Medicine Director, UCLA

Visit the CVI for selected past talks: http://med.stanford.edu/cvi/mission/frontiers-in-cv-science/seminar-videos-2015.html

Available videos feature talks by: Roy P. Vagelos, MD; Jonathan Lindner, MD; Bernard Gersh, MB, ChB, D.Phil; Joseph Hill, MD, PhD; and Joseph Wu, MD, PhD; and many more.

For additional information on the Frontiers in Cardiovascular Science seminar series, and on how to attend, contact CVI Program Manager David L. M. Preston at preston@stanford.edu.

The Frontiers in Cardiovascular Science seminar series features leaders in the cardiovascular field around the country and Stanford.

This informal meetup is meant for faculty, junior faculty and instructors to discuss collaborations or data to be submitted and receive input of aims for grant submissions. Contact Crystal Botham, PhD (cbotham@stanford.edu) to participate in the CVI Faculty Club.November 04, 2015 “Bioengineering control of human stem cell biology” Oscar Abilez, MD, PhD Instructor, Medicine - Cardiovascular Medicine

December 02, 2015 Clint Miller, PhD Instructor, Medicine-Cardiovascular Medicine

MONTHLY CVIFACULTY CLUB

Discuss your latest research or just unwind

with your peers with wine & cheese

First Wednesday, Monthly

4:30 p.m., in Lorry Lokey G1161

c v i . s ta n fo rd .e d u | 15

Our MissionWe provide quantitative assessment of clinical cardiovascular phenotypes for translational research and clinical tri-als. These cardiovascular phenotypes include evaluating cardiac structure and function, measuring carotid intimal thickness and arterial stiffness, and test-ing endothelial function and cardiopul-monary exercise testing.

In collaboration with the Human Im-mune Monitoring Center at Stanford and members of the Cardiovascular Institute, we also offer central blood processing and banking capabilities. In addition, we develop new biomarker platforms and imaging modalities.

Key Initiatives1. Stanford Athletic Screening Program. The BPCL is the core laboratory responsible for the echocar-diographic studies of Stanford Athletic Screening Program and has imaged more than 500 athletes.

2. Stanford Immune Aging Longitudinal Study. The BPCL is the core providing clinical cardiovascular phenotypes for collaboration through the NIH funded projects of the Immunity Transplantation and Infection Institute led by Mark Davis, MD.

3. The Pulmonary Hypertension Wall Center Outcome and Physiology Studies. The BPCL works closely with the Vera Moulton Wall Center for Pulmonary Vascular Disease to provide quantitative echocardiographic assessment of the right heart.

4. The CCML-Stanford Collaborative Effort. Through a close collaboration with the University of Paris and the Marie-Lannelongue surgical center (CCML), the BPCL is providing quantitative analysis of experimental and clinical studies focused on right heart physiology. The CCML is a recognized worldwide center of expertise in pulmonary hypertension (Elie Fadel MD PhD and Olaf Mercier MD PhD).

Clinical Biomarker & Phenotyping Core Lab (BPCL)

Biobank

Stanford CVI Human iPSC Biobank ServiceNormal and patient-derived reprogrammed cardiomyocytes is a tremendous resource for re-searchers and physicians here at Stanford and around the country. Understanding the disease process directly at the population level and observing these cells as surrogates under a myr-iad conditions has the potential to be a game-changer for cardiovascular medical research.

To facilitate research in a dish that allows screening of new compounds or characterization of human disease phenotypes using cardiomyocytes, the Institute created a service by which de-identified PBMC samples from selected patients can be sent to Stanford CVI for repro-gramming free of cost. Please contact Joseph Wu, MD, PhD ( joewu@stanford.edu) or Bio-bank manager, Justin Vincent ( justin81@stanford.edu), with any questions.

SCVI biobank is supported in part by National Heart, Lung and Blood Institute (NHLBI), the California Institute for Regenerative Medicine (CIRM), and the Stanford Cardiovascular Insti-tute (CVI). Stanford iPSC Biobank was recently mentioned in Nature Methods news: http://www.nature.com/nmeth/journal/v12/n2/full/nmeth.3263.html.

Lab Resources

Contact UsFrancois Haddad, MD (fhaddad@stanford.edu) or Ingrid Ibarra, PhD (iibarra@stanford.edu) at CVI.

3DQ Imaging LaboratoryStanford’s 3DQ Imaging Laboratory was established in 1996 at Stanford by Geof-frey Rubin, MD, and Sandy Napel, PhD, Professor of Radiology (General Radiol-ogy) and, by courtesy, Electrical Engi-neering. Today the center is co-directed by Dominik Fleischmann, MD, Profes-sor of Radiology (General Radiology) and Roland Bammer, PhD, Associate Professor (Research) of Radiology.

Currently the lab processes over 1,200 clinical cases per month. Linda Horst, Marc Sofilos, and Shannon Walters are an integral part of the 3DQ Lab manage-ment team.

For more visit: http://3dqlab.stanford.

edu/

c v i . s ta n fo rd .e d u | 16

JULY 2015: Selected Publications

Manganese-Enhanced Magnetic Resonance Imaging Enables In Vivo Confir-

mation of Peri-Infarct Restoration Following Stem Cell Therapy in a Porcine

Ischemia-Reperfusion Model. Dash R, Kim PJ, Matsuura Y, Ikeno F, Metzler

S, Huang NF, Lyons JK, Nguyen PK, Ge X, Wong Po Foo C, McConnell MV,

Wu JC, Yeung AC, Harnish P, Yang PC. J Am Heart Assoc. 2015 Jul 27;4(7).

Reprogramming and transdifferentiation for cardiovascular development

and regenerative medicine: where do we stand? Ebert AD, Diecke S, Chen

IY, Wu JC. EMBO Mol Med. 2015 Jul 16.

Snorkel/Chimney Stent Morphology Predicts Renal Dysfunction After Com-

plex EVAR. Tran K, Ullery BW, Lee JT. Ann Vasc Surg. 2015 Jul 14.

Primary Prevention of Heart Failure in Older Adults. Maron DJ, Hunt SA.JACC Heart Fail. 2015 Jul;3(7):529-30.

Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Ef-

fectively Prevents Experimental In-Stent Restenosis. Wang D, Deuse T,

Stubbendorff M, Chernogubova E, Erben RG, Eken SM, Jin H, Li Y, Busch A,

Heeger CH, Behnisch B, Reichenspurner H, Robbins RC, Spin JM, Tsao PS,

Schrepfer S, Maegdefessel L. Arterioscler Thromb Vasc Biol. 2015 Jul 16.

Exploring Value in Congenital Heart Disease: An Evaluation of Inpatient

Admissions. Shin AY, Hu Z, Jin B, Lal S, Rosenthal DN, Efron B, Sharek PJ,

Sutherland SM, Cohen HJ, McElhinney DB, Roth SJ, Ling XB. Congenit Heart

Dis. 2015 Jul 29.

Learning the Structure of Biomedical Relationships from Unstructured

Text. Percha B, Altman RB. PLoS Comput Biol. 2015 Jul 28;11(7)

Outpatient Pharmacy Expenditures for Children With Serious Chronic Ill-

ness in California, 2010-2012. Swenson SM, Chamberlain LJ, Sanders LM,

Sundaram V, Wise PH. JAMA. 2015 Jul 28;314(4):405-7.

Corrigendum: Simple, standardized incorporation of genetic risk into non-

genetic risk prediction tools for complex traits: coronary heart disease as

an example. Goldstein BA, Knowles JW, Salfati E, Ioannidis JP, Assimes TL. Front Genet. 2015 Jul 7;6:231.

Tunable and reversible drug control of protein production via a self-excis-

ing degron. Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, Plemper RK,

Tsien RY, Lin MZ. Nat Chem Biol. 2015 Sep;11(9):713-20.

Nationwide Population Science: Lessons From the Taiwan National Health

Insurance Research Database. Hsing AW, Ioannidis JP. JAMA Intern Med.

2015 Jul 20.

Modifying Ventricular Fibrillation by Targeted Rotor Substrate Ablation:

Proof-of-Concept from Experimental Studies to Clinical VF. Krummen DE,

Hayase J, Vampola SP, Ho G, Schricker AA, Lalani GG, Baykaner T, Coe TM,

Clopton P, Rappel WJ, Omens JH, Narayan SM. J Cardiovasc Electrophysiol.

2015 Jul 14.

Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hyperten-

sion. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de

Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie

A, Swift AJ, Rabinovitch M, Zamanian RT. Am J Respir Crit Care Med. 2015

Jul 15;192(2):254-7.

Cluster-Randomized Trial of Personalized Site Performance Feedback in

Get With The Guidelines-Heart Failure. DeVore AD, Cox M, Heidenreich PA,

Fonarow GC, Yancy CW, Eapen ZJ, Peterson ED, Hernandez AF. Circ Cardio-

vasc Qual Outcomes. 2015 Jul;8(4):421-7.

Atrial Fibrillation Burden and Short-Term Risk of Stroke: A Case-Crossover

Analysis of Continuously Recorded Heart Rhythm from Cardiac Electronic

Implanted Devices. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J,

Than CT, Keung EK, Singer DE. Circ Arrhythm Electrophysiol. 2015 Jul 14.

High-resolution variable-density 3D cones coronary MRA. Addy NO, Ingle

RR, Wu HH, Hu BS, Nishimura DG. Magn Reson Med. 2015 Sep;74(3):614-21.

Imaging G protein-coupled receptors while quantifying their ligand-bind-

ing free-energy landscape. Alsteens D, Pfreundschuh M, Zhang C, Spoerri

PM, Coughlin SR, Kobilka BK, Müller DJ. Nat Methods. 2015 Jul 13.

Screening ECGs for young competitive athletes: it is complicated. Dubin AM. Curr Opin Pediatr. 2015 Jul 10. [Epub ahead of print]

Activation of the Nuclear Factor Kappa-B Pathway During Postnatal Lung

Inflammation Preserves Alveolarization by Suppressing Macrophage In-

flammatory Protein-2. Hou Y, Liu M, Husted C, Chen C, Thiagarajan K, Johns

JL, Rao SP, Alvira CM. Am J Physiol Lung Cell Mol Physiol. 2015 Jul 10

A Tissue Engineered Chondrocyte Cell-Sheet Induces Extracellular Matrix

Modification to Enhance Ventricular Biomechanics and Attenuate Myocar-

dial Stiffness in Ischemic Cardiomyopathy. Shudo Y, Cohen JE, MacArthur

JW, Trubelja A, Patel J, Edwards BB, Hung G, Fairman AS, Brusalis C,

Hiesinger W, Atluri P, Hiraoka A, Miyagawa S, Sawa Y, Woo YJ, Goldstone A,

Otsuru S. Tissue Eng Part A. 2015 Jul 8.

Postoperative Surveillance and Long-term Outcomes After Endovascular

Aneurysm Repair Among Medicare Beneficiaries. Garg T, Baker LC, Mell MW. JAMA Surg. 2015 Jul 8.

Communication is at the heart of scientific advancement and innovation. This quarter the Stanford Cardiovascular Institute members published over 240 original manuscripts and reviews further contributing to our understanding of cardiovascular biology and disease. In the following pages, we highlight selected manuscripts by our members.

Member Publications

c v i . s ta n fo rd .e d u | 17

Obstructive Sleep Apnea Is an Independent Predictor of Postoperative

Atrial Fibrillation in Cardiac Surgery. Wong JK, Maxwell BG, Kushida CA,

Sainani KL, Lobato RL, Woo YJ, Pearl RG. J Cardiothorac Vasc Anesth. 2015

Mar 26.

Live Video Diet and Exercise Intervention in Overweight and Obese Youth:

Adherence and Cardiovascular Health. Nourse SE, Olson I, Popat RA,

Stauffer KJ, Vu CN, Berry S, Kazmucha J, Ogareva O, Couch SC, Urbina EM,

Selamet Tierney ES. J Pediatr. 2015 Jul 4.

Sex-Stratified Trends in Enrollment, Patient Characteristics, Treat-

ment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary

Syndrome Patients: Insights From Clinical Trials Over 17 Years. Kragholm

K, Halim SA, Yang Q, Schulte PJ, Hochman JS, Melloni C, Mahaffey KW,

Moliterno DJ, Harrington RA, White HD, Armstrong PW, Ohman EM, Van

de Werf F, Tricoci P, Alexander JH, Giugliano RP, Newby LK. Circ Cardiovasc

Qual Outcomes. 2015 Jul;8(4):357-67.

Variation in Use of Pediatric Cardiology Subspecialty Care: A Total Popula-

tion Study in California, 1983 to 2011. Chamberlain LJ, Fernandes SM,

Saynina O, Grady S, Sanders L, Staves K, Wise PH. J Am Coll Cardiol. 2015

Jul 7;66(1):37-44.

Adaptable Hydrogels: Adaptable Hydrogel Networks with Reversible Link-

ages for Tissue Engineering (Adv. Mater. 25/2015). Wang H, Heilshorn SC.

Adv Mater. 2015 Jul;27(25):3710.

AUGUST 2015: Selected Publications

Early surgical intervention or watchful waiting for the management of

asymptomatic mitral regurgitation: a systematic review and meta-analysis.

Goldstone AB, Patrick WL, Cohen JE, Aribeana CN, Popat R, Woo YJ. Ann

Cardiothorac Surg. 2015 May;4(3):220-9.

Novel TIA biomarkers identified by mass spectrometry-based proteomics.

George PM, Mlynash M, Adams CM, Kuo CJ, Albers GW, Olivot JM. Int J

Stroke. 2015 Aug 26.

Microfluidic Single-Cell Analysis of Transplanted Human Induced Pluripo-

tent Stem Cell-Derived Cardiomyocytes After Acute Myocardial Infarction.

Ong SG, Huber BC, Hee Lee W, Kodo K, Ebert AD, Ma Y, Nguyen PK, Diecke S, Chen WY, Wu JC. Circulation. 2015 Aug 25;132(8):762-71.

Comparison of quality-of-life measures after radial versus femoral artery

access for cardiac catheterization in women: Results of the Study of Access

Site for Enhancement of Percutaneous Coronary Intervention for Women

quality-of-life substudy. Hess CN, Krucoff MW, Sheng S, Anstrom KJ, Bar-

ham WB, Gilchrist IC, Harrington RA, Jacobs AK, Mehran R, Messenger JC,

Mark DB, Rao SV. Am Heart J. 2015 Aug;170(2):371-9.

A validated risk model for 1-year mortality after primary prevention

implantable cardioverter defibrillator placement. Heidenreich PA, Tsai V,

Curtis J, Wang Y, Turakhia MP, Masoudi FA, Varosy PD, Goldstein MK. Am

Heart J. 2015 Aug;170(2):281-289.e2.

Multiple Surface Regions on the Niemann-Pick C2 Protein Facilitate Intra-

cellular Cholesterol Transport. McCauliff LA, Xu Z, Li R, Kodukula S, Ko DC,

Scott MP, Kahn PC, Storch J. J Biol Chem. 2015 Aug 20.

Human Engineered Heart Muscles Engraft and Survive Long-Term in a Ro-

dent Myocardial Infarction Model. Riegler J, Tiburcy M, Ebert A, Tzatzalos

E, Raaz U, Abilez OJ, Shen Q, Kooreman NG, Neofytou E, Chen V, Wang M,

Meyer T, Tsao PS, Connolly AJ, Couture LA, Gold JD, Zimmermann WH, Wu JC. Circ Res. 2015 Aug 19.

Aortic Wall Injury Related to Endovascular Therapy for Aortic Coarctation.

Tretter JT, Jones TK, McElhinney DB. Circ Cardiovasc Interv. 2015 Sep;8(9).

Association between blood glucose variability and coronary plaque insta-

bility in patients with acute coronary syndromes. Okada K, Hibi K, Gohbara

M, Kataoka S, Takano K, Akiyama E, Matsuzawa Y, Saka K, Maejima N, Endo

M, Iwahashi N, Tsukahara K, Kosuge M, Ebina T, Fitzgerald PJ, Honda Y,

Umemura S, Kimura K. Cardiovasc Diabetol. 2015 Aug 20;14:111.

Wirelessly powered, fully internal optogenetics for brain, spinal and pe-

ripheral circuits in mice. Montgomery KL, Yeh AJ, Ho JS, Tsao V, Mohan Iyer

S, Grosenick L, Ferenczi EA, Tanabe Y, Deisseroth K, Delp SL, Poon AS. Nat

Methods. 2015 Aug 17.

Risk of cardiac disease and observations on lack of potential predictors by

clinical history among children presenting for cardiac evaluation of mid-

exertional syncope. Miyake CY, Motonaga KS, Fischer-Colbrie ME, Chen L,

Hanisch DG, Balise RR, Kim JJ, Dubin AM. Cardiol Young. 2015 Aug 17:1-7.

Quantitative precision of optical frequency domain imaging: direct compar-

ison with frequency domain optical coherence tomography and intravascu-

lar ultrasound. Kobayashi Y, Kitahara H, Tanaka S, Okada K, Kimura T, Ikeno

F, Yock PG, Fitzgerald PJ, Honda Y. Cardiovasc Interv Ther. 2015 Aug 14.

Why Optimal Medical Therapy Should Be a Universal Standard of Care.

Maron DJ, Boden WE. J Am Coll Cardiol. 2015 Aug 18;66(7):774-6.

A Rapid, High-Quality, Cost-Effective, Comprehensive, and Expandable

Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases.

Wilson KD, Shen P, Fung E, Karakikes I, Zhang A, InanlooRahatloo K, Ode-

gaard J, Sallam K, Davis RW, Lui G, Ashley E, Scharfe C, Wu JC. Circ Res.

2015 Aug 11.

For whom the cells pull: Hydrogel and micropost devices for measuring trac-

tion forces. Ribeiro AJ, Denisin AK, Wilson RE, Pruitt BL. Methods. 2015 Aug 8.

Computational modeling and engineering in pediatric and congenital

heart disease. Marsden AL, Feinstein JA. Curr Opin Pediatr. 2015 Aug 8.

Maternal Asthma, Preterm Birth, and Risk of Bronchopulmonary Dysplasia.

Gage S, Kan P, Lee HC, Gould JB, Stevenson DK, Shaw GM, O’Brodovich HM. J Pediatr. 2015 Aug 5.

A Rising Generation of Diversity in the Vascular Surgery Workforce. Itoga

NK, Woo K, Bismuth J, Bechara C, Grenon M, Mitchell E, Zhou W. Ann Vasc

Surg. 2015 Aug 4.

c v i . s ta n fo rd .e d u | 18

Group visits in the pediatric heart transplant outpatient clinic. Hollander

SA, McDonald N, Lee D, May LJ, Doan LN, Kaufman BD, Rosenthal DN. Pedi-

atr Transplant. 2015 Aug 6.

The central role of muscle stem cells in regenerative failure with aging.

Blau HM, Cosgrove BD, Ho AT. Nat Med. 2015 Aug 6;21(8):854-62.

Invasive physiologic and anatomic multimodality assessment of myocar-

dial bridging. Schwartz JG, Tanaka S, Schnittger I, Tremmel JA. Coron

Artery Dis. 2015 Aug;26 Suppl 1:e38-40.

Assessment of left main artery stenosis with fractional flow reserve is af-

fected by downstream stenosis in the left anterior descending artery. Bing

R, Yong AS, Fearon WF. Coron Artery Dis. 2015 Aug;26 Suppl 1:e35-7.

Structural insights into µ-opioid receptor activation. Huang W, Manglik

A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE,

Livingston KE, Thorsen TS, Kling RC, Granier S, Gmeiner P, Husbands SM,

Traynor JR, Weis WI, Steyaert J, Dror RO, Kobilka BK. Nature. 2015 Aug

20;524(7565):315-21.

Association of an Endovascular-First Protocol for Ruptured Abdominal Aor-

tic Aneurysms With Survival and Discharge Disposition. Ullery BW, Tran K,

Chandra V, Mell MW, Harris EJ, Dalman RL, Lee JT. JAMA Surg. 2015 Aug 5.

Harmonic force spectroscopy measures load-dependent kinetics of indi-

vidual human β-cardiac myosin molecules. Sung J, Nag S, Mortensen KI,

Vestergaard CL, Sutton S, Ruppel K, Flyvbjerg H, Spudich JA. Nat Commun.

2015 Aug 4;6:7931.

The long-term prognostic value of the Q wave criteria for prior myocardial

infarction recommended in the universal definition of myocardial infarc-

tion. Perino AC, Soofi M, Singh N, Aggarwal S, Froelicher V. J Electrocar-

diol. 2015 Jul 7.

Optical delay encoding for fast timing and detector signal multiplexing in

PET. Grant AM, Levin CS. Med Phys. 2015 Aug;42(8):4526.

First among Equals: Nerve Growth Factor in the Pathogenesis of Pulmo-

nary Arterial Hypertension. de Jesus Perez VA. Am J Respir Crit Care Med.

2015 Aug 1;192(3):274-5.

Changes in Risk Profile Over Time in the Population of a Pediatric Heart

Transplant Program. Reinhartz O, Maeda K, Reitz BA, Bernstein D, Luikart

H, Rosenthal DN, Hollander SA. Ann Thorac Surg. 2015 Jul 27.

September 2015: Selected Publications

A semiflexible 64-channel receive-only phased array for pediatric body MRI

at 3T. Zhang T, Grafendorfer T, Cheng JY, Ning P, Rainey B, Giancola M, Ort-

man S, Robb FJ, Calderon PD, Hargreaves BA, Lustig M, Scott GC, Pauly JM,

Vasanawala SS.Magn Reson Med. 2015 Sep 29. doi: 10.1002/mrm.25999.

[Epub ahead of print]

Contractility of single cardiomyocytes differentiated from pluripotent stem

cells depends on physiological shape and substrate stiffness. Ribeiro AJ,

Ang YS, Fu JD, Rivas RN, Mohamed TM, Higgs GC, Srivastava D, Pruitt BL.

Proc Natl Acad Sci USA. 2015 Sep 28.

Susceptibility Loci for Clinical CAD and Subclinical Coronary Atheroscle-

rosis Throughout the Life-Course. Salfati E, Nandkeolyar S, Fortmann SP,

Sidney S, Hlatky MA, Quertermous T, Go AS, Iribarren C, Herrington DM,

Goldstein BA, Assimes TL. Circ Cardiovasc Genet. 2015 Sep 28.

The Incompatibility of Living Systems: Characterizing Growth-Induced

Incompatibilities in Expanded Skin. Buganza Tepole A, Gart M, Purnell CA,

Gosain AK, Kuhl E. Ann Biomed Eng. 2015 Sep 28.

Effect of Sex Differences on Invasive Measures of Coronary Microvascu-

lar Dysfunction in Patients With Angina in the Absence of Obstructive

Coronary Artery Disease. Kobayashi Y, Fearon WF, Honda Y, Tanaka S,

Pargaonkar V, Fitzgerald PJ, Lee DP, Stefanick M, Yeung AC, Tremmel JA.

JACC Cardiovasc Interv. 2015 Sep;8(11):1433-41.

Isolation of skeletal muscle stem cells by fluorescence-activated cell

sorting. Liu L, Cheung TH, Charville GW, Rando TA. Nat Protoc. 2015

Oct;10(10):1612-24. doi: 10.1038/nprot.2015.110. Epub 2015 Sep 24.

Prognostic utility of right atrial emptying fractions in pulmonary arterial

hypertension. Brunner NW, Haddad F, Kobayashi Y, Hsi A, Swiston JR, Gin

KG, Zamanian RT. Pulm Circ. 2015 Sep;5(3):473-80.

The effect of cangrelor and access site on ischaemic and bleeding events:

insights from CHAMPION PHOENIX. Gutierrez JA, Harrington RA, Blanken-

ship JC, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux

P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION

PHOENIX Investigators. Eur Heart J. 2015 Sep 23.

Variation in use of echocardiography among veterans who use the Veterans

Health Administration vs Medicare. Kini V, McCarthy FH, Rajaei S, Epstein

AJ, Heidenreich PA, Groeneveld PW. Am Heart J. 2015 Oct;170(4):805-11.

Efficacy and safety of rivaroxaban in patients with diabetes and nonval-

vular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa

Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke

and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Bansilal S,

Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker

RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz

SD, Piccini JP, Mahaffey KW, Fox KA; ROCKET AF Steering Committee and

Investigators. Am Heart J. 2015 Oct;170(4):675-682.e8.

Rationale and design of the Fractional Flow Reserve versus Angiography

for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow

reserve-guided percutaneous coronary intervention and coronary artery

bypass graft surgery in patients with multivessel coronary artery disease.

Zimmermann FM, De Bruyne B, Pijls NH, Desai M, Oldroyd KG, Park SJ,

Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. Am Heart J. 2015

Oct;170(4):619-626.e2.

Facility variation and predictors of serum potassium monitoring after

initiation of a mineralocorticoid receptor antagonist in patients with heart

failure. Chauhan V, Dev S, Pham M, Lin S, Heidenreich P. Am Heart J. 2015

Sep;170(3):543-9.

c v i . s ta n fo rd .e d u | 19

Rationale and design of the Prospective LongitudinAl Trial of FFRCT:

Outcome and Resource IMpacts study. Pontone G, Patel MR, Hlatky MA,

Chiswell K, Andreini D, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutber-

let M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, de Bruyne

B, Rogers C, Douglas PS. Am Heart J. 2015 Sep;170(3):438-446.e44.

The Undiagnosed Diseases Network of the National Institutes of Health: A

National Extension. Gahl WA, Wise AL, Ashley EA. JAMA. 2015 Sep 16:1-2.

Epicardial FSTL1 reconstitution regenerates the adult mammalian heart.

Wei K, Serpooshan V, Hurtado C, Diez-Cuñado M, Zhao M, Maruyama S, Zhu

W, Fajardo G, Noseda M, Nakamura K, Tian X, Liu Q, Wang A, Matsuura Y,

Bushway P, Cai W, Savchenko A, Mahmoudi M, Schneider MD, van den Hoff

MJ, Butte MJ, Yang PC, Walsh K, Zhou B, Bernstein D, Mercola M, Ruiz-Lozano P. Nature. 2015 Sep 24;525(7570):479-85.

Biochemically engineered stromal cell-derived factor 1-alpha analog

increases perfusion in the ischemic hind limb. Edwards BB, Fairman AS,

Cohen JE, MacArthur JW Jr, Goldstone AB, Woo JB, Hiesinger W, Woo YJ. J

Vasc Surg. 2015 Sep 11.

Protein-engineered scaffolds for in vitro 3D culture of primary adult

intestinal organoids. DiMarco RL, Dewi RE, Bernal G, Kuo C, Heilshorn SC.

Biomater Sci. 2015 Oct 15;3(10):1376-85.

Lean body mass and risk of incident atrial fibrillation in post-menopausal

women. Azarbal F, Stefanick ML, Assimes TL, Manson JE, Bea JW, Li W,

Hlatky MA, Larson JC, LeBlanc ES, Albert CM, Nassir R, Martin LW, Perez MV. Eur Heart J. 2015 Sep 14.

Increased Heart Rate Is Associated With Higher Mortality in Patients With

Atrial Fibrillation (AF): Results From the Outcomes Registry for Better

Informed Treatment of AF (ORBIT-AF). Steinberg BA, Kim S, Thomas L,

Fonarow GC, Gersh BJ, Holmqvist F, Hylek E, Kowey PR, Mahaffey KW, Nac-

carelli G, Reiffel JA, Chang P, Peterson ED, Piccini JP; Outcomes Registry for

Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators

and Patients. J Am Heart Assoc. 2015 Sep 14;4(9).

Ambrisentan and Tadalafil Upfront Combination Therapy in Scleroderma-

Associated PAH. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R,

Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH,

Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis

RE, Chin K, Mathai SC. Am J Respir Crit Care Med. 2015 Sep 11.

Detecting Lymphedema: Bioimpedance Spectroscopy and the Tissue Di-

electric Constant. Rockson SG. Lymphat Res Biol. 2015 Sep;13(3):169.

Mechanisms for the Termination of Atrial Fibrillation by Localized Ablation:

Computational and Clinical Studies. Rappel WJ, Zaman JA, Narayan SM.

Circ Arrhythm Electrophysiol. 2015 Sep 10.

Detection of the Short-Lived Radical Cation Intermediate in the Electrooxi-

dation of N,N-Dimethylaniline by Mass Spectrometry. Brown TA, Chen H,

Zare RN. Angew Chem Int Ed Engl. 2015 Sep 14;54(38):11183-5.

Ex Vivo Expansion and In Vivo Self-Renewal of Human Muscle Stem Cells.

Charville GW, Cheung TH, Yoo B, Santos PJ, Lee GK, Shrager JB, Rando TA.

Stem Cell Reports. 2015 Sep 2.

Novel Approach to a Giant External Iliac Vein Aneurysm Secondary to Post-

traumatic Femoral Arteriovenous Fistula. Thompson PC, Ullery BW, Fleis-chmann D, Chandra V. Vasc Endovascular Surg. 2015 Jul;49(5-6):148-51.

Novel mutations in PIEZO1 cause an autosomal recessive generalized lym-

phatic dysplasia with non-immune hydrops fetalis. Fotiou E, Martin-Alme-

dina S, Simpson MA, Lin S, Gordon K, Brice G, Atton G, Jeffery I, Rees DC,

Mignot C, Vogt J, Homfray T, Snyder MP, Rockson SG, Jeffery S, Mortimer

PS, Mansour S, Ostergaard P. Nat Commun. 2015 Sep 3;6:8085.

Members Only: Hypoxia-Induced Cell-Cycle Activation in Cardiomyocytes.

Sharma A, Wu SM. Cell Metab. 2015 Sep 1;22(3):365-6.

Development of a scalable suspension culture for cardiac differentiation

from human pluripotent stem cells. Chen VC, Ye J, Shukla P, Hua G, Chen

D, Lin Z, Liu JC, Chai J, Gold J, Wu JC, Hsu D, Couture LA. Stem Cell Res.

2015 Aug 13;15(2):365-375.

Medication Initiation Burden Required to Comply with Heart Failure

Guideline Recommendations and Hospital Quality Measures. Allen LA,

Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen

ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM;

American Heart Association’s Get With The Guidelines Heart Failure (GWTG-

HF) Investigators. Circulation. 2015 Aug 27.

Abdominal Aortic Hemodynamics in Intermittent Claudication Patients at

Rest and during Dynamic Pedaling Exercise. Cheng CP, Taylor CA, Dalman RL. Ann Vasc Surg. 2015 Aug 24.

c v i . s ta n fo rd .e d u | 20

Joseph C. Wu, MD, PhDDirector, Stanford Cardiovascular Institute Professor, Dept. of Medicine (Cardiovascular) and Radiology

Robert A. Harrington, MDArthur L. Bloomfield Professor of Medicine Chair, Dept. of Medicine

Stephen J. Roth MD, MPHProfessor and Chief, Pediatric CardiologyDirector, Children’s Heart Center

Ronald L. Dalman, MDWalter C. and Elsa R. Chidester Professor of SurgeryChief, Division of Vascular Surgery

Michael Snyder, PhDProfessor and Chair, Dept. of GeneticsDirector, Stanford Center for Genomics and Personalized Medicine

Dominik Fleischmann, MDProfessor, Dept. of RadiologyChief, Cardiovascular Imaging

Y. Joseph Woo, MDNorman E. Shumway Professor in Cardiothoracic SurgeryChair Dept. of Cardiothoracic Surgery

Kenneth Mahaffey, MDProfessor, Dept. of MedicineVice Chair of Medicine for Clinical Research

Alan Yeung, MDLi Ka Shing Professor of MedicineCo-Chief (Clinical), Division of Cardiovascular Medicine

Mark Nicolls, MDAssociate Professor, Dept. of MedicineChief, Pulmonary and Critical Care Medicine

Paul Yock, MDMartha Meier Weiland Professor of Bioengineering and Medicine; and Professor, by courtesy, of Mechanical EngineeringDirector of Biodesign

Tom Quertermous, MDWilliam G. Irwin Professor of MedicineCo-Chief (Research), Division of Cardiovascular Medicine

Marlene Rabinovitch, MDDwight and Vera Dunlevie Professor in Pediatric Cardiology

Leadership